Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04778410 · ClinicalTrials.gov registry record · Phase 2
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT04778410: Clinical Trial Phase 2 study, sponsored by Gilead Sciences.
NCT04778410 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 54 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04778410, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
The goal of this clinical study is to learn more about the safety and dosing of the study drug, magrolimab (Mag), in combination with anti-leukemia therapies in participants with acute myeloid leukemia (AML).
Primary Outcome
CR rate was the percentage of participants who achieved CR (CR without minimal residual disease (CRMRD-) or complete remission with positive or unknown minimal residual disease (CRMRD+/unk)) as determined by the investigator based on prespecified criteria while on study prior to initiation of any new anti-cancer therapy. CRMRD- and CRMRD+/unk were defined as neutrophils \>1.0 ×10\^9/L; platelets \>100 × 10\^9/L and \<5% bone marrow blasts. Absence of circulating blasts and blasts with Auer rods;
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
- DRUG Etoposide
- DRUG Mitoxantrone
- DRUG Magrolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2021-06-28 |
| Est. Completion | 2024-03-04 |
| Phase | Phase 2 |
Why NCT04778410 stopped before completion
NCT04778410 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 5 interventions - of which Venetoclax is the first listed.
NCT04778410 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04778410 about?
NCT04778410 is a clinical study titled "Study of Magrolimab Combinations in Participants With Myeloid Malignancies". The goal of this clinical study is to learn more about the safety and dosing of the study drug, magrolimab (Mag), in combination with anti-leukemia therapies in participants with acute myeloid leukemia (AML).
What is the current status of trial NCT04778410?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2021-06-28. Estimated completion is 2024-03-04.
What interventions are being tested in trial NCT04778410?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), Etoposide (DRUG), Mitoxantrone (DRUG), Magrolimab (DRUG).
Who is sponsoring clinical trial NCT04778410?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04778410's enrollment target sits among peer trials
54 1160th of 2000 higher than 830 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI